Pulsed Field Ablation and Innovative Therapies Dominate 2024 in Atrial Fibrillation Treatment
• Pulsed-field ablation (PFA) gained prominence with multiple FDA approvals, offering shorter and safer ablation procedures for atrial fibrillation (AF).
• The OPTION trial demonstrated that left atrial appendage occlusion (LAAO) with Watchman FLX, when added to catheter ablation, reduces bleeding compared to oral anticoagulants.
• The EPIC-CAD trial showed that edoxaban alone is superior to edoxaban plus antiplatelet therapy in AF patients with stable coronary artery disease, reducing adverse events.
• New European AF guidelines introduced the AF-CARE pathway, emphasizing comorbidity management, stroke prevention, symptom reduction, and dynamic assessment.
© Copyright 2025. All Rights Reserved by MedPath